Clinical Trials Logo

Filter by:
NCT ID: NCT03163043 Completed - Healthy Clinical Trials

Protein Requirements for Active Children

IAAO-C
Start date: October 22, 2016
Phase: N/A
Study type: Interventional

Nutritional requirements for dietary amino acids in children have traditionally been determined utilizing the nitrogen balance technique, which is prone to underestimating protein requirements. As a result, there is a need to re-evaluate recommendations in order to characterize how dietary amino acid needs may be modulated by physical activity in healthy, active children. The purpose of this study is to measure the protein requirement in children (boys and girls) using the IAAO technique in the presence of a variable intensity exercise stimulus. It is hypothesized that the present study will deem current amino acid requirements to be underestimates of appropriate amino acid requirements for this population.

NCT ID: NCT03162926 Completed - Clinical trials for Type 1 Diabetes Mellitus

A Safety and Tolerability Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus

Start date: July 5, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this trial is to test if VC-02™ combination product can be implanted subcutaneously in subjects with Type 1 Diabetes and maintained safely for up to four (4) months.

NCT ID: NCT03162796 Completed - Clinical trials for Arthritis, Psoriatic

A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)

Discover-1
Start date: August 24, 2017
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active Psoriatic Arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.

NCT ID: NCT03162055 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease COPD

Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

AERISTO
Start date: May 25, 2017
Phase: Phase 3
Study type: Interventional

This is a phase IIIb randomised, double-blind, double-dummy, multicentre, parallel group, 24 week study to assess the efficacy and safety of Glycopyrronium/Formoterol Fumarate (GFF) fixed-dose combination 7.2/4.8 μg 2 inhalations twice daily compared to Umeclidinium/Vilanterol (UV) 62.5/25 μg fixed-dose combination 1 inhalation once daily in Patients with moderate to very severe COPD.

NCT ID: NCT03161483 Completed - Clinical trials for Lupus Erythematosus, Systemic

A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

Start date: August 31, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this Phase 2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of an oral treatment regimen of CC-220 versus placebo in adult subjects with active systemic lupus erythematosus. Approximately 280 subjects with a documented diagnosis of SLE will be randomized 2:2:1:2 to receive CC-220 (0.45 mg QD, 0.3 mg QD or 0.15 mg QD) or identically appearing placebo.

NCT ID: NCT03160898 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)

FORTITUDE-ALS
Start date: July 24, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study was to assess the effect of CK-2127107 (hereafter referred to as reldesemtiv) versus placebo on respiratory function and other measures of skeletal muscle function in patients with ALS.

NCT ID: NCT03160885 Completed - Atopic Dermatitis Clinical Trials

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)

ECZTRA 2
Start date: June 12, 2017
Phase: Phase 3
Study type: Interventional

Primary objective: To evaluate the efficacy of tralokinumab compared with placebo in treating moderate to severe atopic dermatitis (AD). Secondary objectives: To evaluate the efficacy of tralokinumab on severity and extent of AD, itch, and health related quality of life compared with placebo. Maintenance objective: To evaluate maintenance of effect with continued tralokinumab dosing up to 52 weeks compared to placebo for subjects achieving clinical response at Week 16.

NCT ID: NCT03160703 Completed - Oral Hygiene Clinical Trials

Study to Investigate the Stain Control of Two Stannous Fluoride Dentifrices

Start date: July 10, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate and compare the stain build up of two stannous fluoride (SnF2) / sodium tripolyphosphate (STP) dentifrices of differing abrasivity levels, with a marketed standard fluoride dentifrice and a marketed SnF2 dentifrice.

NCT ID: NCT03160547 Completed - Critical Illness Clinical Trials

The Effect of Higher Protein Dosing in Critically Ill Patients

EFFORT
Start date: November 21, 2017
Phase: N/A
Study type: Interventional

The investigator will investigate the effects of higher protein/amino acid dosing (≥2.2 g/kg/d) vs usual protein/amino acid dosing (≤1.2 g/kg/d) on clinical outcomes in nutritionally high risk ill patients.

NCT ID: NCT03160482 Completed - Thyroid Nodule Clinical Trials

PACE4 in Thyroid Cancer

Start date: May 15, 2017
Phase:
Study type: Observational

The investigation of thyroid nodules is limited by the fact that up to 49% of the fine needle aspirations (FNA) performed are of "indeterminate cytological signification". Moreover, no fully reliable molecular marker for thyroid cancer have been described. The goal of this project is to study the expression of a specific kind of protein convertase in benign and in malignant thyroid nodules to determine its potential as a biomarker.